tatins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) are widely used clinically to decrease serum cholesterol levels. 1 Recent studies have focused on the pleiotropic effects of statins, which are independent of their lipid-lowering effects, such as stimulation of fibrinolysis by altering the levels and activities of tissue-plasminogen activator (t-PA) and plasminogen activator inhibitor-1. 2, 3 Statins also reduce hemostasis by inhibiting platelet activation and the procoagulation cascade, and by augmenting the anticoagulation cascade. 4 Thus, statins appear to effectively enhance the fibrinolytic activity of t-PA. An experimental study in animals has shown that combination treatment with a statin and t-PA after stroke increases cerebral blood flow and reduces infarct volume as compared with fibrinolytic treatment alone; 5 however, data in humans are lacking. Prompt reperfusion of the occluded artery is crucial to limiting the size of an infarct. The present study was designed to test the hypothesis that statin treatment before the onset of acute myocardial infarction (AMI) contributes to prompt coronary artery reperfusion and smaller infarct size in patients with AMI who receive fibrinolytic therapy. We examined the relationship between statin pretreatment and the rate of coronary artery reperfusion assessed according to the Thrombolysis In Myocardial Infarction (TIMI) 6 flow grade and infarct size in patients with AMI who were given fibrinolytic therapy. The degree of myocardial damage before and after reperfusion therapy was also assessed on the basis of electrocardiographic (ECG) findings.
tatins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) are widely used clinically to decrease serum cholesterol levels. 1 Recent studies have focused on the pleiotropic effects of statins, which are independent of their lipid-lowering effects, such as stimulation of fibrinolysis by altering the levels and activities of tissue-plasminogen activator (t-PA) and plasminogen activator inhibitor-1. 2, 3 Statins also reduce hemostasis by inhibiting platelet activation and the procoagulation cascade, and by augmenting the anticoagulation cascade. 4 Thus, statins appear to effectively enhance the fibrinolytic activity of t-PA. An experimental study in animals has shown that combination treatment with a statin and t-PA after stroke increases cerebral blood flow and reduces infarct volume as compared with fibrinolytic treatment alone; 5 however, data in humans are lacking. Prompt reperfusion of the occluded artery is crucial to limiting the size of an infarct. The present study was designed to test the hypothesis that statin treatment before the onset of acute myocardial infarction (AMI) contributes to prompt coronary artery reperfusion and smaller infarct size in patients with AMI who receive fibrinolytic therapy. We examined the relationship between statin pretreatment and the rate of coronary artery reperfusion assessed according to the Thrombolysis In Myocardial Infarction (TIMI) 6 flow grade and infarct size in patients with AMI who were given fibrinolytic therapy. The degree of myocardial damage before and after reperfusion therapy was also assessed on the basis of electrocardiographic (ECG) findings.
Methods

Study Population
We enrolled 310 consecutive patients with ST-segment elevation AMI (mean age 60±11 years; 268 men, 42 women) who fulfilled the following criteria: (1) no history of myocardial infarction; (2) admission to Yokohama City University Medical Center within 12 h of symptom onset; (3) absence of conditions precluding the evaluation of ST-segment changes on ECG (left or right bundle-branch block, ventricular pacing); and (4) received fibrinolytic therapy. The diagnosis of AMI was based on typical chest pain lasting at least 30 min, ST-segment elevation of at least 1 mm in 2 contiguous leads, and a subsequent increase in the serum creatine kinase (CK) level to more than twice the upper limit of normal. Cardiac symptoms occurring within 48 h before the onset of AMI were defined as preinfarction angina. 7 In Yokohama City University Medical Center, in principle, patients without any contraindications for fibrinolysis were given 200 mg oral aspirin, 50 IU/kg intravenous heparin, and 
Definitions
We measured white blood cell and neutrophil counts, and triglycerides, total cholesterol, high-density lipoproteincholesterol and low-density lipoprotein-cholesterol-concentrations in serum on admission, using standard methods. Hypercholesterolemia was considered present if it had been previously diagnosed or if the total cholesterol concentration on admission was higher than 220 mg/dl or the low-density lipoprotein-cholesterol concentration on admission was higher than 140 mg/dl. Whether statins had been administered before admission was determined from detailed interviews or medical records.
Coronary Angiography (CAG)
CAG was performed as soon as possible after admission. The perfusion status of the infarct-related artery was assessed according to the TIMI study classification. The grade of collateral filling in the infarct-related artery was evaluated as described by Rentrop et al, 8 and a good collateral channel was defined as grade 2 or 3. We initially evaluated TIMI flow grade in the infarct-related artery 29 min after fibrinolysis on average. If TIMI flow grade at this time was 0, 1, or 2, percutaneous coronary intervention, including stent implantation, was immediately performed. As a rule, immediate percutaneous coronary intervention was not done in patients with TIMI flow grade 3. Reperfusion time was defined as the time from symptom onset to the time when TIMI flow grade ≥2 was confirmed angiographically. In patients who had an improvement in symptoms and a decrease in STsegment elevation before cardiac catheterization in whom TIMI flow grade ≥2 was confirmed on the first angiogram, reperfusion time was defined as the time from symptom onset until the time of confirming such clinical findings.
ECG Analysis
A 12-lead ECG was recorded on admission and 1 h after the final angiogram, at a paper speed of 25 mm/s and an amplification of 10 mm/mV. The isoelectric line was defined as the level of the preceding TP segment. ST-segment elevation was measured 80 ms after the J point by a single cardiologist who was unaware of all other clinical data. STsegment elevation was calculated as the sum of ST-segment elevations in leads I, aVL, and V1-6 for anterior AMI and leads II, III, aVF, and V5-6 for non-anterior AMI. 9 In addition to ST-segment measurement, we calculated the 32-point QRS score, 10 which has been validated in patients with AMI and strongly correlates with infarct size. 11 
Cardiac Enzyme Study
Blood samples were obtained on admission, at 3-h intervals during the first 24 h, at 6-h intervals for the next 2 days, and then daily until discharge. Peak levels of CK and the areas under the curve (AUC) for CK were calculated by the linear-trapezoidal method. 12 
Statistical Analysis
Data are expressed as mean values ± standard deviation (SD) for continuous variables and as percentages for categorical variables. Analysis of variance was used to calculate P-values for continuous variables. Chi-square analysis or Fisher's exact test was used to compare categorical variables. Differences were considered statistically significant at P<0.05. Multivariate analysis was used to identify clinical predictors of larger infarct size, defined as the upper tertile of AUCs for CK among the variables associated (P<0.10) with this index on univariate analysis. Odds ratios and 95% confidence intervals were calculated. Data were analyzed with the SPSS statistical package (Release 10, SPSS Inc, Chicago, IL, USA).
Results
Among the 310 study patients, 39 had received statin treatment for at least 1 month before admission 13 
Patient Characteristics
The baseline characteristics of the patients in the 2 groups are summarized in Table 1 . There were no significant differences between the 2 groups in age, smoking, preinfarction angina, heart rate, systolic blood pressure, Killip class, white blood cell count, lipid profiles on admission, time from onset to admission, time from admission to fibrinolysis, time from fibrinolysis to angiography, percutaneous coronary intervention, or stent implantation. Patients in the statin group were less likely to be male and to have anterior AMI, and were more likely to have coronary risk factors such as hypertension, hyperlipidemia, and diabetes mellitus and to have received long-term therapy with drugs such as aspirin, angiotensin-converting enzyme inhibitors, angiotensin-receptor blocker, and β-blockers before admission. There was a trend toward a lower neutrophil count on admission in the statin group, but the difference did not reach statistical significance.
ECG and CAG Findings
ECG and CAG findings are shown in Table 2 and Figs 1, 2. Patients in the statin group had a smaller sum of ST-segment elevation and a lower QRS score, both on admission and 1 h later. When the analysis was limited to patients with anterior AMI, QRS scores were significantly lower in the statin group on admission and 1 h later. In addition, the sum of ST-segment elevation on admission was similar in the 2 groups, and there was a trend toward a lower ST-segment elevation 1 h later in the statin group, but the difference did not reach statistical significance.
There were no significant differences between the 2 groups in multivessel disease or collateral circulation. Initial TIMI flow grade did not differ between the 2 groups. Among the 120 patients with an initial TIMI flow grade 0 or 1, the achievement of TIMI flow grade ≥2 after passing the guidewire through the culprit lesion was more frequent in the statin group (Fig 1) . The rate of final TIMI flow grade 3 was slightly, but not significantly, higher in the statin group.
Infarct Size and Predictors of Larger Infarct Size
Peak CK and AUC of CK were lower in the statin group ( terior AMI, there were trends toward lower peak CK levels and smaller AUCs for CK in the statin group, but the differences did not reach statistical significance. In the multivariate analysis, statin pretreatment was a negative determinant, and Killip class ≥2 on admission, anterior AMI, and initial TIMI flow grade 0 or 1 were positive determinants of a larger infarct size as defined by the upper tertile of AUC for CK ( Table 3) . Other variables such as multivessel disease, final TIMI flow grade ≤2, and percutaneous coronary intervention, which were associated with a larger infarct size on univariate analysis (P<0.10), were not significant predictors of a larger infarct size.
Discussion
Our study showed that statin pretreatment reduced infarct size in patients with AMI who received fibrinolytic therapy. Although statin pretreatment was not associated with restoration of TIMI flow grade ≥2 at initial angiography, among patients with initial TIMI flow grade 0 or 1, the achievement TIMI flow grade ≥2 was more frequent in the statin group. At final angiography, the rate of TIMI flow grade 3 tended to be higher in the statin group. Moreover, statin pretreatment was associated with reduced myocardial damage during ischemia and reperfusion, as assessed by ECG findings.
Statins and Fibrinolysis
An experimental study in animals has shown beneficial effects of combination treatment with a statin and t-PA on cerebrovascular patency after stroke. 5 Following plaque disruption, statins promote vascular fibrinolysis by exerting various inhibitory actions on platelet deposition and aggregation, coagulation factors, and rheology. 14, 15 However, our study found no significant difference in the coronary artery reperfusion rate as assessed by initial TIMI flow grade after fibrinolytic therapy between patients with and without statin pretreatment. Susceptibility to coronary fibrinolytic treatment is influenced by a number of related factors, including the age of the thrombus, its composition, the characteristics of the surrounding plasma, and the temporal evolution of the occluding thrombosis. 16, 17 Perhaps the small dose of t-PA (approximately half the standard dose) used in our study was inadequate and the timing of initial coronary angiography (mean, 29 min from fibrinolysis) was too early to demonstrate an effect of statin pretreatment on coronary artery reperfusion after fibrinolytic therapy. When the analysis was limited to patients with an occluded infarct-related artery 1. Comparison of the achievement of Thrombolysis In Myocardial Infarction (TIMI) flow grade ≥2 after passing the guidewire through the culprit lesion in the statin and non-statin groups. It was more frequent in patients who had initial TIMI flow grade 0 or 1 (statin group, n=16; non-statin group, n=104).
Fig 2.
Comparisons of QRS scores on ECG at admission and 1 h later in the statin and non-statin groups. AMI, acute myocardial infarction. Tables 1,2. on the initial angiogram, coronary artery reperfusion with TIMI flow grade ≥2 after passing the guidewire through the culprit lesion was more frequently associated with statin pretreatment, suggesting that the thrombus was more fragile. This finding may imply that statins partially enhance the efficacy of t-PA.
Statins and Myocardial Damage
In the early stages of AMI, the degree of ST-segment elevation and the evolution of abnormal Q waves may reflect the severity of myocardial damage. [18] [19] [20] Greater ST-segment elevation implies ongoing severe myocardial injury, and higher QRS scores imply broader transmural myocardial damage. In our study, patients who received statin pretreatment had a smaller magnitude of ST-segment elevation and lower QRS scores on admission as well as after reperfusion. The ECG findings on admission are not affected by myocardial damage occurring after reperfusion therapy, such as reperfusion injury or distal embolization, which suggests that statin pretreatment was associated with less myocardial damage during ischemia and reperfusion, resulting in a smaller infarct size as assessed by peak CK levels and AUC for CK. Although the precise mechanisms underlying the protective effects of statins against ischemia -reperfusion injury are unclear, statins have shown vasculoprotective and cardioprotective effects in experimental studies. Statins may improve endothelial function by decreasing expression of endothelial adhesion molecules, increasing nitric oxide bioavailability, and attenuating the production of reactive oxygen species. 2, 21, 22 In addition, statins are thought to stabilize plaque by decreasing lipid oxidation, inflammation, matrix metalloproteinase-2, and cell death and by increasing the content of tissue inhibitor of metalloproteinase-1 and collagen; these effects might reduce distal embolization. 23 Furthermore, statins have been shown to open mitochondrial adenosine triphosphate-sensitive potassium channels, suggesting pharmacological ischemic preconditioning effects. 24, 25 These effects might contribute to reduced myocardial damage during ischemia -reperfusion. Several studies have demonstrated that statin pretreatment reduces microvascular and myocardial damage after coronary intervention in patients with AMI. 13, 26 
Study Limitations
First, this was a single-center retrospective study performed in a relatively small number of patients. Second, we could not precisely assess the effects of the pretreatment period or the dose of statins. Furthermore, we could not analyze the effects of differences in statin type because of the small number of patients. Third, patients with statin pretreatment were more likely to have received drugs such as aspirin, angiotensin-converting enzyme inhibitors, angiotensin-receptor blocker, and β-blockers before admission. Although these medications may affect clinical outcomes, they were not found to be associated with larger infarct size. In addition, patients with statin pretreatment were more likely to have hypertension, hyperlipidemia, and diabetes mellitus. Patients given statin pretreatment may thus have been more aggressively treated in terms of diet, exercise, or other lifestyle interventions.
Conclusions
The present study shows that statin pretreatment is associated with a smaller infarct size in patients with AMI who receive fibrinolytic therapy. Our results provide evidence that statins have cardioprotective effects and enhance the effectiveness of t-PA.
